Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group study-Reference-Cited by-同舟云学术

Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group study

Published:2020-11-24 Issue:3 Volume:192 Page:551-559
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Wästerlid Tove¹²^ORCID,Oren Gradel Kim³⁴^ORCID,Eloranta Sandra¹^ORCID,Glimelius Ingrid¹⁵^ORCID,El‐Galaly Tarec C.⁶,Frederiksen Henrik⁷⁸,Smedby Karin E.¹²

Affiliation:

1. Department of Medicine Solna Division of Clinical Epidemiology Karolinska Institutet and Karolinska University Hospital StockholmSweden

2. Department of Haematology Karolinska University Hospital Stockholm Sweden

3. Centre for Clinical Epidemiology OUH and Institute of Clinical ResearchUniversity of Southern Denmark OdenseDenmark

4. OPEN– Odense Patient Data Exploratory Network Odense University Hospital Odense Denmark

5. Department of Immunology, Genetics and Pathology Unit of Oncology Uppsala University Uppsala Sweden

6. Department of Hematology Aalborg University AalborgDenmark

7. Department of Haematology Odense University Hospital (OUH) OdenseDenmark

8. Academy of Geriatric Cancer Research Odense University Hospital Odense Denmark

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17250

Reference40 articles.

1. Trends in hematological cancer in the elderly in Denmark, 1980–2012

2. Unmet needs in the scientific approach to older patients with lymphoma

3. Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project

4. Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma-A population-based study from Sweden

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of trial inclusion criteria on outcomes in DLBCL patients treated with R-CHOP in the first line: a Danish nationwide study;Leukemia & Lymphoma;2024-09-03

2. Appropriate Treatment Intensity for Diffuse Large B-Cell Lymphoma in the Older Population: A Review of the Literature;Hematology Reports;2024-05-24

3. Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma;Journal of Clinical and Experimental Hematopathology;2023-12-26

4. Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL);Haematologica;2022-11-17

5. Host‐related factors and cancer: Malnutrition and non‐Hodgkin lymphoma;Hematological Oncology;2022-04-18